Abstract:Chemotherapeutics have been recommended as the standard protocol for inoperable patients with triple -negative breast cancer (TNBC) at advanced stage, yet limited success has been achieved in prolonging sur-vival rates by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Ferroptosis has become a powerful modality of no-apoptotic cell death, which can effectively evade chemo-resistance in apoptotic pathways. Herein, we propose an active-targeting small-molecular self-assembly nano-prodrug for co-delivery of chemother-apeutics (CPT), Ferrocene (Fc) and GPX4 inhibitor (RSL3) to overcome the chemo-resistance from tradi-tional apoptotic pathways. In this nano-prodrug, the disulfide linkage not only serves as a GSH-responsive trigger, but also exhibits a stable self-assembly behavior that forms nanoparticle. Interestingly, the RSL3 can be loaded during this self-assembly process that forms a three-components nano-prodrug. In tumor environment, the high GSH level can disassemble the nano-prodrug to trigger the release of the parent drug, which can improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis. In dif-ferent TNBC mice models, the nano-prodrug is encapsulated into RGD-modified phospholipid micelles (DSPE-PEG20 0 0-RGD) and exhibits high anti-tumor and anti-metastasis efficacy, especially in orthotopic models. The application of ferroptosis to assist the enhancement of chemotherapeutics may serve as a promising strategy for TNBC treatment.Statement of significanceChemotherapeutics have been recommended as the standard of care for palliative and adjuvant treatment in patients with triple-negative breast cancer (TNBC), yet limited success has been achieved in prolong-ing the overall survival of patients by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Thus, the co-delivery of the apoptosis and ferroptosis drug may overcome or evade the resistance in chemotherapy-induced apoptotic pathways and provide a promising strategy to combat TNBC. In this work, we developed a small-molecular self-assembly nano-prodrug for co-delivery of chemotherapeutics (CPT), Ferrocene (Fc) and ferroptosis resistance inhibitor (RSL3), which could overcome the chemo-resistance and improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis.(c) 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Combination Therapy to Overcome Ferroptosis Resistance by Biomimetic Self-Assembly Nano-Prodrug

A Self-Assembly Nano-Prodrug for Triple-Negative Breast Cancer Combined Treatment by Ferroptosis Therapy and Chemotherapy

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy

A Supramolecular Self-Assembled Nanoprodrug for Enhanced Ferroptosis Therapy

A Biomimetic Nanodrug Self-Assembled from Small Molecules for Enhanced Ferroptosis Therapy

A Glutathione-Responsive Polyphenol - Constructed Nanodevice for Double Roles in Apoptosis and Ferroptosis

Mitochondria-Targeted Prodrug Nanoassemblies for Efficient Ferroptosis-Based Therapy via Devastating Ferroptosis Defense Systems

In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Ferroptosis resistance in cancer cells: nanoparticles for combination therapy as a solution

Delivery of a System Xc−inhibitor by a Redox-Responsive Levodopa Prodrug Nanoassembly for Combination Ferrotherapy

Multi-Enzyme Cascade-Triggered Nitric Oxide Release Nanoplatform Combined with Chemo Starvation-like Therapy for Multidrug-Resistant Cancers

Asymmetric silicon phthalocyanine based nanoparticle with spatiotemporally targeting of mitochondria for synergistic apoptosis-ferroptosis antitumor treatment

A Self‐Assembly Combined Nano‐Prodrug to Overcome Gemcitabine Chemo‐Resistance of Pancreatic Tumors

ROS-Responsive and Self-Catalytic Nanocarriers for a Combination of Chemotherapy and Reinforced Ferroptosis against Breast Cancer

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

A multimodal therapeutic nano-prodrug as oxidative stress amplifier induces apoptosis and ferroptosis for cancer therapy

Ferrous-Supply-Regeneration Nanoengineering for Cancer-Cell-Specific Ferroptosis in Combination with Imaging-Guided Photodynamic Therapy.

A Nanozyme-Based Drug Delivery System to Amplify Ferroptosis Via MET Inhibition and Photodynamic Therapy

Advance on combination therapy strategies based on biomedical nanotechnology induced ferroptosis for cancer therapeutics

Precisely Self-Cooperative Nanoassembly Enables Photothermal/Ferroptosis Synergistic Tumor Eradication